Please ensure Javascript is enabled for purposes of website accessibility
top of page

Kalytera Announces Issuance

Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel

Kalytera Therapeutics, Inc. (KALY.V) (KALTF) (the “Company” or “Kalytera”) today announced that the Company has elected to issue 396,015 common shares of the Company (“Common Shares”) to The Salzman Group in payment of an invoice issued under the services agreement with The Salzman Group previously announced on December 7, 2017 (the “Agreement”). Under the Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease.


bottom of page